Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells, Annals of Oncology, vol.9, issue.suppl 5, pp.129-132, 1998. ,
DOI : 10.1093/annonc/9.suppl_5.S129
Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.539-546, 2002. ,
DOI : 10.1007/s00262-002-0315-1
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.12, issue.3, pp.1853-1860, 2007. ,
DOI : 10.4049/jimmunol.173.12.7125
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.532-538, 2002. ,
Treatment of Metastatic Melanoma with Autologous Melan-A/Mart-1-Specific Cytotoxic T Lymphocyte Clones, Journal of Investigative Dermatology, vol.129, issue.12, pp.2835-2842, 2009. ,
DOI : 10.1038/jid.2009.144
Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells, The Journal of Immunology, vol.175, issue.7, pp.4797-4805, 2005. ,
DOI : 10.4049/jimmunol.175.7.4797
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells, Proceedings of the National Academy of Sciences, vol.71, issue.2, pp.16168-16173, 2002. ,
DOI : 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0
Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage, Clinical Cancer Research, vol.12, issue.3, pp.764-771, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1544
URL : http://clincancerres.aacrjournals.org/content/clincanres/12/3/764.full.pdf
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency, The Journal of Experimental Medicine, vol.6, issue.11, pp.2673-2682, 2008. ,
DOI : 10.1038/76292
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, Journal of Experimental Medicine, vol.180, issue.1, pp.35-42, 1994. ,
DOI : 10.1084/jem.180.1.35
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection., Proceedings of the National Academy of Sciences, vol.91, issue.14, pp.6458-6462, 1994. ,
DOI : 10.1073/pnas.91.14.6458
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, European Journal of Immunology, vol.42, issue.6, pp.1786-1794, 2010. ,
DOI : 10.4049/jimmunol.170.10.5103
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor, Trends in Immunology, vol.23, issue.7, pp.325-328, 2002. ,
Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans, The Journal of Experimental Medicine, vol.61, issue.4, pp.485-494, 2002. ,
DOI : 10.1046/j.1523-1747.2001.01363.x
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunology, Immunotherapy, vol.175, issue.4, pp.515-526, 2007. ,
DOI : 10.4049/jimmunol.175.10.7046
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes, Cancer Immunology, Immunotherapy, vol.320, issue.4, pp.553-566, 2008. ,
DOI : 10.4049/jimmunol.174.9.5249
Erratum: Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nature Medicine, vol.6, issue.6, pp.707-710, 2000. ,
DOI : 10.1038/76292
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, Journal of Immunology, vol.160, issue.4, pp.1750-1758, 1998. ,
High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clinical Cancer Research, vol.6, issue.4, pp.1459-1467, 2000. ,
CD25 Blockade protects T Cells from Activation-induced Cell Death (AICD) via Maintenance of TOSO Expression, Scandinavian Journal of Immunology, vol.17, issue.3, pp.206-215, 2009. ,
DOI : 10.4049/jimmunol.172.11.6519
Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression, Experimental Hematology, vol.38, issue.5, pp.351-362, 2010. ,
DOI : 10.1016/j.exphem.2010.02.006
Role of Cytokines in Thymus- Versus Peripherally Derived-Regulatory T Cell Differentiation and Function, Frontiers in Immunology, vol.4, issue.155, 2013. ,
DOI : 10.3389/fimmu.2013.00155
URL : https://hal.archives-ouvertes.fr/hal-01560639
T Cells for the Treatment of Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.24, issue.31, pp.5060-5069, 2006. ,
DOI : 10.1200/JCO.2006.07.1100
Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients, The Journal of Immunology, vol.170, issue.4, pp.2161-2169, 2003. ,
DOI : 10.4049/jimmunol.170.4.2161
Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis, Melanoma Research, vol.12, issue.5, pp.491-498, 2002. ,
DOI : 10.1097/00008390-200209000-00011
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides, Clinical Cancer Research, vol.18, issue.23, pp.6485-6496, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-1516
Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue, The Journal of Immunology, vol.164, issue.2, pp.1125-1131, 2000. ,
DOI : 10.4049/jimmunol.164.2.1125